Arpida Announces Safe Results from Phase I Trial with Iclaprim

Arpida Ltd. has announced the results of a Phase I trial with intravenous iclaprim in volunteers with varying degrees of renal and hepatic impairment and obesity. The results of the study confirm that iclaprim was safe and well-tolerated in all these special populations.

Furthermore, the predictable pharmacokinetics observed in these populations would suggest that monitoring may not be required. The study adds important information for a New Drug Application as it could provide useful guidance for clinicians for treating patients with underlying dysfunctional conditions. The subjects included in this study covered the full range from normal body weight to severely obese, from normal renal function to severely impaired renal function and from normal hepatic function to moderately impaired hepatic function.

For further information please contact:

Bo Skaaning Jensen

Tel: +45 70 22 23 65

Email: bsjensen@arpida.dk

Or visit: www.arpida.com